AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

A potent mix of bureaucratic red tape and adverse court rulings is deterring U.S. startups and small businesses from ...

We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

Despite a recently-agreed $7.4 billion settlement, the Sackler family has yet to fully account for its role in America's ...

Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...

These super high-flying US stocks have soared 222%, 122%, and 150%, respectively, in 2025. Let's take a look why.

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Incorporating heavy workout routines, strict diets, and taking countless pills can be tiring and not an optimal choice for ...

Artificial intelligence (AI) has the potential to drive profound economic and societal transformations. Estimates from McKinsey suggest that generative AI could contribute between $2.6 trillion and $4 ...